Zhejiang Jingxin Pharmaceutical Co., Ltd (Jingxin Pharma) was established in 1974. It is an integrated enterprise which has its own R&D department, API manufacturing facilities and Preparation manufacturing facilities. There are four manufacturing sites in the Co., they are: Zhejiang Xinchang site for finished product; Zhejiang Shangyu site for API; Jiangxi Shangrao Guangfeng site for Chemical intermediate; Inner Mongolia site for Traditional Chinese Medicine. Jingxin Pharma became the listed company of Shen Zhen Stock Exchange in Luly, 2007.

Jingxin focuses on manufacturing of 3 series of drugs such as Cardiovascular drug, Antibiotics and Antidepressant. More than 160 products have been registered in China. The main dosage forms include Tablets, Capsules, Powder for Suspensions, Powder for Injections, Large Volume Injections, Oral Liquids and APIs. Among which, the annual manufacturing capacity for APIs is 2, 000 tons, 1.2 billion for Tabs and Caps, 30 million for Powder for Injections, 5 million for Large Volume Preparations.

Jingxin Pharma is one of the biggest production bases for the APIs of quinolones; The sales volume of Simvastatin Tablets rank the first in our domestic market; Ciprofloxacin Tablets and Levofloxacin Hydrochloride Tablets also have a large market share.